Jacobio’s SHP2 inhibitor (JAB-3068) independently developed by Jacobio Pharmaceuticals Co., Ltd. entered human clinical trials for multiple solid tumors in the United States (April 2018) and China (November 2018).
In February 2019, the US Food and Drug Administration (FDA) also awarded JAB-3068 orphan drug designation for the treatment of esophageal cancer, providing substantial support for the drug’s global development for this indication.
JAB-3068 is a novel protein tyrosine phosphatase inhibitor (PTPi) with independent intellectual property rights. To date, three pharmaceutical companies worldwide are engaged in the Phase I clinical studies with anti-cancer agent in this field. JAB-3068 functions through both target therapy and immuno-oncology mechanisms. As an oral monotherapy, it has demonstrated significant anti-tumor activity; it can also promote the tumor-inhibitory immune function, offering opportunities to be combined with PD1 antibody and other drugs.
Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R & D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R & D center in Boston, USA, to strengthen and coordinate the global development of new drugs.